A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
(BE HEARD I)
Recruitment Status: recruiting as of August 2020.
Estimated Completion Date: May 2023
Sponsors and Collaborators: UCB Biopharma SRL
Locations: multiple locations please refer to link above for further information.
Contact: UCB Cares 1844599 ext 2273